Latest news
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’ - BioSpaceBioSpace · Thu, 06 Aug 2026 12:35:10 GMTContext Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock TitanStock Titan · Thu, 06 Aug 2026 01:23:30 GMTVaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:26:35 GMTSanofi’s New CEO Highlights Pipeline Prioritization - DCAT Value Chain InsightsDCAT Value Chain Insights · Thu, 30 Jul 2026 07:00:00 GMTSanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions - BioSpaceBioSpace · Thu, 30 Jul 2026 07:00:00 GMT